Возможности персонализированной медицины в борьбе с хроническими неинфекционными заболеваниями: достижения и перспективы

С тех пор как более 15 лет назад был расшифрован геном человека, произошел огромный скачок в развитии геномных и постгеномных технологий. Внедрением этих технологий в клиническую практику занимается персонализированная медицина: разрабатываются новые методы оценки риска, диагностики и терапии заболеваний с учетом индивидуальных особенностей пациента. Значительные успехи достигнуты в расшифровке генетических основ хронических неинфекционных заболеваний, ведется поиск новых маркеров риска развития осложнений и мишеней для действия препаратов. В данном обзоре освещаются перспективные направления развития персонализированной медицины, задачи, стоящие перед современными учеными, и возможные пути их решения.

1. Collins F. Has the revolution arrived? Nature. 2010;464(7289):674-5. https://doi.org/10.1038/464674a

2. Hood L, Rowen L. The human genome project: big science transforms biology and medicine. Genome Medicine. 2013;5(9):79. https://doi.org/10.1186/gm483

3. Концевая А.В., Муканеева Д.К., Мырзаматова А.О., Баланова Ю.А., Худяков М.Б., Драпкина О.М. Экономический ущерб факторов риска, обусловленный их вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации в 2016 году. Кардиоваскулярная терапия и профилактика. 2020;19(1):48-55. https://doi.org/10.15829/1728-8800-2020-1-2396

4. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937-52. https://doi.org/10.1016/S0140-6736(04)17018-9

5. Leon-Mimila P, Wang J, Huertas-Vazquez A. Relevance of MultiOmics Studies in Cardiovascular Diseases. Frontiers in Cardiovascular Medicine. 2019;6:91. https://doi.org/10.3389/fcvm.2019.00091

6. Федеральная служба государственной статистики. Демографический ежегодник России 2019. Статистический сборник. - М.: Росстат, 2019. - 252с. ISBN 978-5-89476-479-5

7. Won H-H, Natarajan P, Dobbyn A, Jordan DM, Roussos P, Lage K et al. Disproportionate Contributions of Select Genomic Compartments and Cell Types to Genetic Risk for Coronary Artery Disease. PLOS Genetics. 2015;11(10):e1005622. https://doi.org/10.1371/journal.pgen.1005622

8. van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. Circulation Research. 2018;122(3):433-43. https://doi.org/10.1161/CIRCRESAHA.117.312086

9. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults. Journal of the American College of Cardiology. 2018;72(16):1883-93. https://doi.org/10.1016/j.jacc.2018.07.079

10. Said MA, Verweij N, van der Harst P. Associations of Combined Genetic and Lifestyle Risks With Incident Cardiovascular Disease and Diabetes in the UK Biobank Study. JAMA Cardiology. 2018;3(8):693-702. https://doi.org/10.1001/jamacardio.2018.1717

11. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nature Genetics. 2019;51(2):237-44. https://doi.org/10.1038/s41588-018-0307-5

12. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-206. https://doi.org/10.1038/nature14177

13. Karlsson Linnér R, Biroli P, Kong E, Meddens SFW, Wedow R, Fontana MA et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nature Genetics. 2019;51(2):245-57. https://doi.org/10.1038/s41588-018-0309-3

14. Baragetti A, Palmen J, Garlaschelli K, Grigore L, Pellegatta F, Tragni E et al. Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. Journal of Internal Medicine. 2015;277(4):478-87. https://doi.org/10.1111/joim.12282

15. D’Mello MJJ, Ross SA, Briel M, Anand SS, Gerstein H, Paré G. Association Between Shortened Leukocyte Telomere Length and Cardiometabolic Outcomes: Systematic Review and Meta-Analysis. Circulation: Cardiovascular Genetics. 2015;8(1):82-90. https://doi.org/10.1161/CIRCGENETICS.113.000485

16. van der Harst P, de Windt LJ, Chambers JC. Translational Perspective on Epigenetics in Cardiovascular Disease. Journal of the American College of Cardiology. 2017;70(5):590-606. https://doi.org/10.1016/j.jacc.2017.05.067

17. Costantino S, Libby P, Kishore R, Tardif J-C, El-Osta A, Paneni F. Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. European Heart Journal. 2018;39(47):4150-8. https://doi.org/10.1093/eurheartj/ehx568

18. Muka T, Koromani F, Portilla E, O’Connor A, Bramer WM, Troup J et al. The role of epigenetic modifications in cardiovascular disease: A systematic review. International Journal of Cardiology. 2016;212:174-83. https://doi.org/10.1016/j.ijcard.2016.03.062

19. Breitling LP, Salzmann K, Rothenbacher D, Burwinkel B, Brenner H. Smoking, F2RL3 methylation, and prognosis in stable coronary heart disease. European Heart Journal. 2012;33(22):2841-8. https://doi.org/10.1093/eurheartj/ehs091

20. Nakatochi M, Ichihara S, Yamamoto K, Naruse K, Yokota S, Asano H et al. Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related to cardiovascular disease. Clinical Epigenetics. 2017;9(1):54. https://doi.org/10.1186/s13148-017-0353-3

21. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Frontiers in Endocrinology. 2018;9:402. https://doi.org/10.3389/fendo.2018.00402

22. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G et al. Use of Circulating MicroRNAs to Diagnose Acute Myocardial Infarction. Clinical Chemistry. 2012;58(3):559-67. https://doi.org/10.1373/clinchem.2011.173823

23. Seronde M-F, Vausort M, Gayat E, Goretti E, Ng LL, Squire IB et al. Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLOS ONE. 2015;10(11):e0142237. https://doi.org/10.1371/journal.pone.0142237

24. Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P et al. Circulating miR-29a, Among Other UpRegulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2014;63(9):920-7. https://doi.org/10.1016/j.jacc.2013.09.041

25. Costantino S, Libby P, Kishore R, Tardif J-C, El-Osta A, Paneni F. Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. European Heart Journal. 2018;39(47):4150-8. https://doi.org/10.1093/eurheartj/ehx568

26. Young AI, Wauthier F, Donnelly P. Multiple novel gene-by-environment interactions modify the effect of FTO variants on body mass index. Nature Communications. 2016;7(1):12724. https://doi.org/10.1038/ncomms12724

27. Bentley AR, Sung YJ, Brown MR, Winkler TW, Kraja AT, Ntalla I et al. Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nature Genetics. 2019;51(4):636-48. https://doi.org/10.1038/s41588-019-0378-y

28. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The Human Microbiome Project. Nature. 2007;449(7164):804-10. https://doi.org/10.1038/nature06244

29. Драпкина О.М., Кабурова А.Н. Кишечная микробиота - новый спутник на маршруте сердечно-сосудистых заболеваний: неожиданные роли старых соседей. Рациональная Фармакотерапия в Кардиологии. 2016;12(1):66-71. https://doi.org/10.20996/1819-6446-2016-12-1-66-71

30. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X et al. Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk. New England Journal of Medicine. 2013;368(17):1575-84. https://doi.org/10.1056/NEJMoa1109400

31. Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C et al. Alterations of the Gut Microbiome in Hypertension. Frontiers in Cellular and Infection Microbiology. 2017;7:381. https://doi.org/10.3389/fcimb.2017.00381

32. Li H, Liu B, Song J, An Z, Zeng X, Li J et al. Characteristics of Gut Microbiota in Patients with Hypertension and/or Hyperlipidemia: A Cross-Sectional Study on Rural Residents in Xinxiang County, Henan Province. Microorganisms. 2019;7(10):399. https://doi.org/10.3390/microorganisms7100399

33. Khan MJ, Gerasimidis K, Edwards CA, Shaikh MG. Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature. Journal of Obesity. 2016;2016:7353642. https://doi.org/10.1155/2016/7353642

34. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 2020;382(16):1520-30. https://doi.org/10.1056/NEJMoa1913805

35. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJG, Zeiher AM et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nature Cell Biology. 2012;14(3):249-56. https://doi.org/10.1038/ncb2441

36. Dichgans M, Pulit SL, Rosand J. Stroke genetics: discovery, biology, and clinical applications. The Lancet Neurology. 2019;18(6):587-99. https://doi.org/10.1016/S1474-4422(19)30043-2

37. Wei Y, Wang D, Yang H, Cao H. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome. PLOS ONE. 2015;10(7):e0132561. https://doi.org/10.1371/journal.pone.0132561

38. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, FunckBrentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407-77. https://doi.org/10.1093/eurheartj/ehz425

39. Ежов М.В., Сергиенко И.В, Рожкова Т.А., Кухарчук В.В., Коновалов Г.А., Мешков А.Н. и др. Диагностика и лечение семейной гиперхолестеринемии (российские рекомендации). Вестник современной клинической медицины. 2017;10(2):72-9. https://doi.org/10.20969/VSKM.2017.10(2).72-79